Professor Langley was honoured to speak at the All-Party Parliamentary Group (APPG) on Prostate Cancer at the House of Commons this week, joining fellow clinicians, researchers, and policymakers to discuss the future of prostate cancer diagnostics and care across the UK.
During the session, Professor Langley shared insights from a collaborative project with Medefer and the Surrey and Sussex Cancer Alliance, aimed at developing a new model to identify and test men who may have been missed in the traditional primary care pathway. The initiative focused on improving access to PSA testing through targeted outreach and streamlined diagnostics, helping to address gaps in early detection and reduce delays in referral.
This work reflects Professor Langley’s ongoing commitment to innovation in prostate cancer care and his leadership in advancing equitable screening strategies across the region.
For further information the presentation slides and minutes of the meeting can be seen here
A groundbreaking new clinical trial—the LDR BURST Study—is set to begin recruitment. Led by Dr Carla Perna and Dr William Hayhurst, the trial will compare two advanced radiotherapy techniques: Low Dose Rate (LDR) Brachytherapy and Stereotactic Body Radiotherapy (SBRT).
Professor Stephen Langley of Royal Surrey Cancer Centre, alongside Professor Frank Chinegwundoh of St George’s University of London, have written a letter to the editor of The Times in response to the article “Screening every man for prostate cancer isn’t as helpful as it sounds.”
On 26 March 2025, Professor Langley and colleagues led a landmark initiative by bringing the Man Van to the House of Commons, offering on-site prostate cancer testing to Members of Parliament and parliamentary staff.
The University of Surrey has conferred an Honorary Doctorate upon Professor Langley, in recognition of his pioneering contributions to prostate cancer detection and treatment, and his leadership in advancing research and care across Surrey and beyond.
The treatment selector table will help you to discuss with your partner and your healthcare team if you are suitable for prostate brachytherapy.
Prostate brachytherapy is the only minimally invasive surgical treatment option recommended by NICE
Latest data from The Prostate Brachytherapy Centre shows
The Prostate Cancer Charity is aiming to put prostate cancer on the top of everyone’s agenda to show it really does matter.
The Prostate Brachytherapy Advisory Group has released a video entitled Prostate Brachytherapy….because relationships matter’ to highlight the impact that treatment choice may have on relationships.